The estimated Net Worth of Yuri Pikover is at least $664 Thousand dollars as of 29 March 2018. Yuri Pikover owns over 3,734 units of Savara Inc stock worth over $664,131 and over the last 7 years Yuri sold SVRA stock worth over $0.
Yuri has made over 3 trades of the Savara Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Yuri bought 3,734 units of SVRA stock worth $33,606 on 29 March 2018.
The largest trade Yuri's ever made was buying 100,000 units of Savara Inc stock on 7 June 2017 worth over $475,000. On average, Yuri trades about 30,747 units every 59 days since 2017. As of 29 March 2018 Yuri still owns at least 153,734 units of Savara Inc stock.
You can see the complete history of Yuri Pikover stock trades at the bottom of the page.
Yuri's mailing address filed with the SEC is 6836 BEE CAVE ROAD, BUILDING III, SUITE 200, AUSTIN, TX, 78746.
Over the last 8 years, insiders at Savara Inc have traded over $2,203,958 worth of Savara Inc stock and bought 6,103,761 units worth $15,290,245 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Savara Inc executives and independent directors trade stock every 29 days with the average trade being worth of $348,922. The most recent stock trade was executed by Matthew Pauls on 28 December 2023, trading 84,000 units of SVRA stock currently worth $395,640.
savara pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. the company’s lead product, aerovanc is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant staphylococcus aureus (mrsa) infection in patients with cystic fibrosis (cf). for more information, please see savara’s website at www.savarapharma.com or www.aerovanc.com
Savara Inc executives and other stock owners filed with the SEC include: